Physician profile
Julie C Ormiston
NPI 1225042344
$3,156.37
in general payments reported to CMS, 2019-2025
23 companies · $757 in 2025
The $757 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $336 · 2023: $928 · 2024: $804 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.78 | 2021-2025 | |
| Novo Nordisk INC | $446.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $388.30 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $310.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $177.11 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.44 | 2021-2025 | Jardiance, Glyxambi, Trijardy Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.41 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $141.89 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $123.76 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.07 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $84.83 | 2024-2025 | |
| Astellas Pharma US INC | $70.92 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $66.25 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $54.02 | 2023-2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $40.45 | 2021-2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $35.42 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $34.24 | 2022-2025 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $28.68 | 2023-2024 | |
| Axsome Therapeutics, INC. | $24.77 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $20.10 | 2022 | |
| Alkermes, INC. | $19.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.77 | 2022 | |
| Hologic Sales and Service, LLC | $14.87 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ormiston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.